Molnupiravir

Also known as EIDD-2801 or MK-4482. KEI blogs 2021. October 4. U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts IP Terms, Contains Donation Clause and Very Limited Technology Transfer License. 2021. October 4. US government rights… Continue Reading

U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts IP Terms, Contains Donation Clause and Very Limited Technology Transfer License

Knowledge Ecology International (KEI) has obtained a copy of the $1.2 billion contract between the U.S. government and Merck to advance purchase 1,696,629 treatment courses of molnupiravir, an investigational COVID-19 drug that is taken in pill form. (PDF Link) According… Continue Reading

US government rights in patents on Molnupiravir, based upon funding of R&D at Emory University

Molnupiravir, the oral pill that is showing promising results as a potential treatment for covid-19, was invented at Emory University with U.S. government funds. After more than six years of non-clinical testing, Emory licensed molnupiravir to Ridgeback Biotherapeutics to continue… Continue Reading

KEI Comments on NIH Exclusive License to Ridgeback for FDA-approved Ebola Treatment

(Update: On April 30, 2021, the NIH sent a response to KEI’s comments.) On March 30, 2021, Knowledge Ecology International (KEI) filed comments regarding the National Institute of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID), “Prospective Grant… Continue Reading